Immunogenic Hepatitis E Virus Polypeptides for Vaccine and Diagnostics Development

This technology comprises specific hepatitis E virus (HEV) antigenic polypeptides. HEV causes epidemic and sporadic cases of hepatitis outbreaks with a mortality rate as high as 20% for pregnant women. In order to address this problem, CDC scientists carried out thorough HEV antigen screenings and subsequently developed recombinant proteins that efficiently model major HEV neutralization epitope(s). These recombinant proteins may be considered as candidates for the development of an HEV subunit vaccine, as well as for the development of highly sensitive and specific diagnostic tests.

Real-time PCR Assays for Human Bocavirus Detection and Diagnosis

CDC researchers have developed a real-time PCR assay for the detection and viral-load quantitative estimations of human bocavirus (HBoV) from clinical specimens. At present, there have been few reports on the epidemiology, geographic distribution or clinical features of HBoV infection. Additionally, symptoms affiliated with bocavirus infections overlap with numerous other respiratory illnesses. This CDC assay provides sensitive, specific, and quantitative detection of HBoV in patients with respiratory illness by a method of real-time PCR targeting the HBoV NS1 and NP-1 genes.

Therapeutic, Bifunctional Janus Microparticles with Spatially Segregated Surface Proteins and Methods of Production

CDC researchers have developed a fabrication process to create bifunctional microparticles displaying two distinct proteins that are spatially segregated onto a single hemispheric surface. At present, there is no described way of producing biological microparticles with two distinct types of separated proteins. Bifunctional Janus particles generated by the CDC approach possess biologically relevant, native conformation proteins attached to a biologically unreactive and safe substrate.

Heterocyclic P2Y14 Antagonists for the Treatment of Various Conditions

The technology discloses composition of compounds that are highly selective P2Y14 receptor antagonists,
with moderate affinity with insignificant antagonism of other P2Y receptors. These compounds might provide a
treatment for patients for various disease conditions, including lung inflammation, kidney inflammation,
asthma, diabetes, obesity, and neuropathic pain of diverse states. In vivo data using mouse lines with the
receptor knocked out in specific tissues showed that P2Y14 receptor antagonists act on adipocytes to improve

Intralipid as a Contrast Agent to Enhance Subsurface Blood Flow Imaging

This technology includes a blood flow imaging method that allows for a higher density of smaller particles to be detected. Current imaging methods that are based on Doppler measurements are limited by the discontinuity in the capillary flow in the space between red blood cells. The core technology is to use a scattering agent to enhance capillary flow or microcirculation. This technology has been tested for optical coherence Doppler tomography, but can be expended to any Doppler based flow imaging techniques such as laser speckle imaging.

A Novel Therapy/Companion Diagnostic (BAM15 And mtDNA) for Sepsis and Sepsis-induced Acute Kidney Injury

This technology includes a therapy and companion diagnostic which can be used for the early diagnosis and treatment of sepsis and sepsis-induced acute kidney injury (AKI). Mitochondrial damage plays a key role in sepsis-induced acute kidney injury BAM15 [2-ftuorophenyl){6-[(2- fluorophenyl)am ino]{1 ,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine] is a mitochondrial uncoupler that protects mitochondria with more specificity and less cytotoxicity than other uncouplers. Mitochondrial DNA (mtDNA) is a damage associated molecular pattern that is increased in human sepsis.

Species-Independent A3 Adenosine Receptor Agonists Which May Be Useful for Treating Ischemia, Controlling Inflammation, and Regulating Cell Proliferation

This invention claims species-independent agonists of A3AR, specifically (N)-methanocarba adenine nucleosides and pharmaceutical compositions comprising such nucleosides. The A3 adenosine receptor (A3AR) subtype has been linked with helping protect the heart from ischemia, controlling inflammation, and regulating cell proliferation. Agonists of the human A3AR subtype have been developed that are also selective for the mouse A3AR while retaining selectivity for the human receptor.

Device for Selective Partitioning of Frozen Cellular Products

Cryopreservation using liquid nitrogen frozen polyvinyl bags allows for storing cellular materials for extended periods while maintaining their activity and viability. Such bags are commonly used in the clinic to store blood products including blood cells, plasma, hematopoietic stem cells, umbilical cord blood for future uses including transplantation. These materials, typically obtained in limited quantities, may be of great therapeutic value, as is the case of stem cells or cord blood derived cells which can be used to potentially treat a number of diseases.

N-Methanocarba Adenosine Derivatives and Their Dendrimer Conjugates as A3 Receptor Agonists

This technology relates to specific (N)-methanocarba adenine nucleosides that have been developed and dendrimers that connect these compounds to create molecules with multiple targets. Dendrimers are essentially repeated molecular branches presenting the core receptor-binding molecules. The compounds synthesized function as agonists and antagonists of a receptor of the G-protein coupled receptor (GPCR) superfamily.
Subscribe to Ophthalmology